ArticleYonago acta medica2025
A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.
Article in Yonago acta medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bladder high-grade urothelial carcinoma in adolescent patient with failed renal transplant: a case report and literature review.International journal of surgery case reports · 2026Article
- Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of malignancy following long-term immunosuppression is increased in organ transplant recipients. We report a case of a patient with right ureteral and bladder cancer after living donor kidney transplantation for chronic glomerulonephritis and who was administered chemotherapy and immune checkpoint inhibitors. A 75-year-old male, 20 years post-living donor kidney transplantation for chronic glomerulonephritis, presented with malignant cells in urinary cytology. Despite initial treatments including transurethral resection of the bladder tumor, the tumor progressed to high-grade urothelial carcinoma. Computerized tomography results showed a right ureteral tumor and multiple lymph node metastases. Therefore, the patient underwent systemic chemotherapy with four cycles of gemcitabine and carboplatin. Pembrolizumab was administered due to rapid cancer progression; however, the cancer progressed further, and the patient was treated palliatively. The patient was treated with an immune checkpoint inhibitor with a reduced dose of immunosuppressive drugs with no rejection during the treatment course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.